Recent Updates
Recently added Catalysts

RVU120

Phase 2

Advanced Solid Tumors | Small molecule | Oncology |cbdMD, Inc.|Last Updated: Jul 28, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment14

FDA Designations

No designations recorded

Clinical trial landscape

RVU120 · 1 trial · 3 indications

Phase 2 1
NCT06987058RVU120 Rollover StudyAdvanced Solid Tumors
ENROLLING BY_INVITATION14 Analytics
PHASE2ENROLLING BY_INVITATION
RVU120 Rollover Study
Advanced Solid Tumors
NCT0698705814
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of Adverse Events (Safety and Tolerability)
12 months

Number and grade of adverse events assessed by CTCAE v5.0

Secondary Endpoints

Duration of response
12 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
RVU120 single agentEXPERIMENTALStudy intervention is assigned in accordance with the parent protocol and consists of RVU120-based treatment.

Interventions

NameTypeDescription
RVU120DRUGRVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: 1. The participant is enrolled in a RVU120 clinical study and receiving RVU120-based treatment given alone or in combination for at least 5 cycles. 2. The participant is currently benefiting from, and expected to continue to benefit from, RVU120-based treatment according to the ...

Countries:PolandSpain
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Advanced Solid Tumors")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Frequently asked questions about RVU120

What is RVU120 used for?

RVU120 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is also being evaluated in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome. The drug is currently in Phase 2 clinical development.

Who is developing RVU120?

RVU120 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical trials of RVU120 in oncology indications.

What phase is RVU120 in?

RVU120 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied in a Phase 2 trial for advanced solid tumors, acute myeloid leukemia, and high-risk myelodysplastic syndrome.

What clinical trials is RVU120 in?

RVU120 is being studied in a Phase 2 rollover study with the identifier NCT06987058. This trial is enrolling by invitation and has an enrollment of 14 participants. The study is being conducted in Poland and Spain and includes patients with advanced solid tumors, acute myeloid leukemia, and high-risk myelodysplastic syndrome.

Is RVU120 a targeted therapy?

RVU120 is a small molecule being studied in a biomarker-selected patient population. The Phase 2 trial for RVU120 is uncontrolled, meaning it does not use a control group, and it is not randomized or double-blinded. The trial enrolls adults aged 18 years and older.